DB13345ApprovedSmall molecule
Dihydroergocristine is an ergot alkaloid used to delay progressive mental decline in conditions like Alzheimer's. Dihydroergocristine is part of the ergoloid mixture products.
- Mechanism
- Curator reviewed · 2 references
Dihydroergocristine mechanism of action seems to be related to a noncompetitive antagonistic activity in the serotonin receptors as well as a double partial agonist/antagonist activity in dopaminergic and adrenergic receptors. In Alzheimer studies, dihydroergocristine act as a direct inhibitor of γ-secretase.
- Primary indication
- Dihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.Curator reviewed · 6 structured indications
- Formula / weight
- C35H41N5O5 · 611.743 g/mol (avg)
- First approval
- United States, 1980
- Also known as
- 9,10-dihydroergocristine · DHEC
- Code names
- GNF-Pf-3462
Resolves to
Clinical / RWD
Structure
InChIKey
DEQITUUQPICUMR-HJPBWRTMSA-NSMILES[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)CTargets
Transporters
What you can answer from here — as of September 23, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Dihydroergocristine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account